Wall Street brokerages forecast that Omeros Co. (NASDAQ:OMER) will report $8.77 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Omeros’ earnings, with the lowest sales estimate coming in at $3.44 million and the highest estimate coming in at $14.10 million. Omeros reported sales of $13.76 million in the same quarter last year, which indicates a negative year-over-year growth rate of 36.3%. The business is expected to issue its next earnings report on Thursday, March 7th.
According to Zacks, analysts expect that Omeros will report full year sales of $16.60 million for the current fiscal year, with estimates ranging from $11.29 million to $21.90 million. For the next year, analysts forecast that the firm will post sales of $97.97 million, with estimates ranging from $25.24 million to $170.70 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Omeros.
Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The company had revenue of $4.61 million during the quarter, compared to the consensus estimate of $3.07 million. During the same period last year, the firm earned ($0.16) EPS.
Shares of Omeros stock opened at $12.25 on Friday. The company has a market capitalization of $608.70 million, a P/E ratio of -15.51 and a beta of 3.54. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.00.
A number of large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in Omeros by 7.2% during the second quarter. Rhumbline Advisers now owns 44,746 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 3,021 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Omeros by 1.8% in the third quarter. TIAA CREF Investment Management LLC now owns 244,374 shares of the biopharmaceutical company’s stock valued at $5,965,000 after acquiring an additional 4,260 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in shares of Omeros by 24.7% in the third quarter. Tocqueville Asset Management L.P. now owns 23,700 shares of the biopharmaceutical company’s stock valued at $579,000 after acquiring an additional 4,700 shares in the last quarter. First Interstate Bank raised its stake in shares of Omeros by 100.0% in the third quarter. First Interstate Bank now owns 10,000 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of Omeros by 2.1% in the third quarter. Morgan Stanley now owns 283,507 shares of the biopharmaceutical company’s stock valued at $6,920,000 after acquiring an additional 5,967 shares in the last quarter. Institutional investors own 47.50% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.